ClinicalTrials.gg
Active, not recruitingNCT06023134Updated Nov 17, 2026

Clinical Characteristics and Outcomes of Patients With Pulmonary Hypertension Associated Right Heart Failure

An observational study in Right Heart Failure and Pulmonary Hypertension, sponsored by Jingyi Ren. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Jingyi Ren · Observational

How we know

Updated Nov 17, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
800
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 377 studies in Heart Failure with a site in China — 162 open to participants now, 182 under way, 18 of them phase 3. Heart Failure · China.

Planned enrollment
60th of 130
800 · median 554
Started
2015
with 10 others
Observational
130 of 377
64 open now
Primary completion
2027-09
later than 119 of 181 live
Registered
215th of 377
by date

Among the 377 studies in Heart Failure with a site in China, this one is the 60th largest by planned enrollment of the 130 observational ones that give a count, is one of 11 that started in 2015, is one of 130 observational ones, reaches primary completion later than 119 of the 181 other live ones, and was the 215th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

162 of the 377 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Heart Failure with a site in China, or all of them as a file.
02

Study summary

The study aims to describe the clinical characteristics and clarify the predictors of the short- and long-term outcomes of RHF patients, further assist the diagnosis, risk stratification and treatment of RHF.

Read the detailed description

Right heart failure(RHF) is a clinical syndrome with symptoms, signs, and evidence of right ventricular systolic and/or diastolic dysfunction. For many years, it was largely neglected in the consideration of left-sided heart failure, while it is now evident that RHF is not only common but its presence also strongly contributes to increased morbidity and mortality. The in-hospital mortality of RHF is 7%, and the 30-day readmission rate is 20%. Therefore, diagnosis, potential treatment strategies, and prognosis improvement have become an unmet need in the field of cardiovascular disease.

In clinical practice, accurate diagnosis of RHF is the key to timely initiation of treatment and improvement of prognosis. Although current guidelines recommend clinical symptoms and signs combined with echocardiography, cardiac magnetic resonance, and other imaging means to evaluate right heart dysfunction for comprehensive diagnosis of right heart failure, the key diagnostic indicators included are inconsistent, the weight ratio of each indicator is different, the diagnostic threshold is not uniform, and the lack of comprehensive diagnostic model system brings great challenges to clinical practice.

This study aims to integrate multiple clinical biomarkers, imaging, and hemodynamic data to describe the clinical characteristics, establish noninvasive easy-to-use diagnosis models for right heart failure, and explore the risk factors for short- and long-term poor prognosis in patients with RHF.

03

Conditions studied

  • Right Heart Failure
  • Pulmonary Hypertension

Keywords

  • Right heart failure
  • Prognosis
  • Right ventricular function
  • Pulmonary hypertension
  • Biomarkers
  • diagnosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The participants who met the indications for right heart catheterization were monitored by hemodynamics and evaluated cardiac function by echocardiography. Those who met the diagnostic criteria for pulmonary hypertension were included in the pulmonary hypertension group, those who also met the diagnostic criteria for right heart failure were included in the right heart failure group, and the rest of the patients were included in the control group.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥18 years at the time of consent
  2. Acceptation of right heart catheterization examination
  3. Able to perform the entire protocol

Exclusion criteria

Exclusion Criteria:

  1. of less than 1 year based on the investigator's clinical judgment
  2. Pregnant or nursing
  3. Planned to undergo heart transplantation or device implantation
  4. Acute coronary syndrome, uncontrolled severe arrhythmia and shock.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
800 participants (estimated)
Patient registry
No

Groups and cohorts

  • Control group

    Participants met the indication for right heart catheterization but did not meet the diagnostic criteria for pulmonary hypertension and right heart failure.

    Diagnostic Test: Echocardiography · Diagnostic Test: Right heart catheterization

  • Pulmonary Hypertension group

    Participants were classified according to the 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension, meaning that a mean pulmonary artery pressure (mPAP) ≥20 mmHg was defined as PH.

    Diagnostic Test: Echocardiography · Diagnostic Test: Right heart catheterization

  • Right heart failure group

    Right heart failure was considered present when RV fractional area change (FAC) was \<35% or tricuspid annular systolic velocity (RV S') was \<9.5 cm/s or tricuspid annular plane systolic excursion (TAPSE) \<17mm.

    Diagnostic Test: Echocardiography · Diagnostic Test: Right heart catheterization

Interventions

  • Diagnostic testEchocardiography

    Echocardiography will be used for specific right ventricular measurements or findings: TAPSE, TAPSE:PASP ratio, tissue Doppler velocity at lateral tricuspid annulus, fractional area change, right ventricular strain, right ventricular hypertrophy, right atrial size, volumes, ejection fraction, tricuspid and pulmonary regurgitation, inferior vena cava diameter and collapsibility, shift of interventricular septum, further assisting the diagnosis of RHF.

  • Diagnostic testRight heart catheterization

    Right heart catheterization is the "gold standard" for the diagnosis of PH. It also allows for direct measurement of intracardiac and pulmonary pressures, as well as cardiac output, and is commonly used to estimate right ventricular preload and afterload.

06

What researchers measure

Primary outcomes

  1. Time to first event of adjudicated CV death mortality or adjudicated HHF

    The composite primary endpoint for this trial is the time to first event of adjudicated CV death or adjudicated hospitalization for heart failure (HHF) in patients with right heart failure.

    Time frame: 24 weeks

Secondary outcomes

  1. Occurrence of adjudicated HHF (first and recurrent)

    any hospital admission due to HHF in 24 weeks

    Time frame: 24 weeks

  2. Time to adjudicated CV death

    any CV death in 24 weeks

    Time frame: 24 weeks

  3. Time to all-cause mortality

    any all-cause mortality in 24 weeks

    Time frame: 24 weeks

  4. Time to first all-cause hospitalisation

    any hospital admission in 24 weeks

    Time frame: 24 weeks

  5. Composite of time to first event of all-cause mortality and all cause hospitalisation

    The composite primary endpoint for this trial is the time to first event of all-cause mortality and all cause hospitalisation in patients with pulmonary hypertension

    Time frame: 24 weeks

  6. Change in NYHA class from baseline at week 24

    Patients are assessed for NYHA class at each admission

    Time frame: 24 weeks

  7. Changes in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) from baseline over time

    Change from baseline to week 24 in N-terminal pro-brain natriuretic peptide (NT-proBNP).Baseline value was defined as the mean of all available measurements at the time of the first right heart catheterization

    Time frame: 24 weeks

  8. Change in liver functions from baseline over time

    Change of transaminase or bilirubin from baseline to week 24 .Baseline value was defined as the mean of all available measurements at the time of the first right heart catheterization

    Time frame: 24 weeks

  9. Change in renal function from baseline over time

    Change of estimated Glomerular Filtration Rate from baseline to week 24. The baseline value was defined as the mean of all available measurements at the time of the first right heart catheterization

    Time frame: 24 weeks

  10. Change in echocardiographic data from baseline over time

    Change from baseline to week 24 in echocardiographic data. Baseline value was defined as the mean of all available measurements at the time of the first right heart catheterization

    Time frame: 24 weeks

  11. Change in ECG data from baseline over time

    Change from baseline to week 24 in ECG data.Baseline value was defined as the mean of all available measurements at the time of the first right heart catheterization

    Time frame: 24 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2015 (actual). Primary completion is estimated for Sep 2027, 152 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Sep 2025 → Sep 2027 and completion Dec 2025 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2023
First posted
Sep 5, 2023
StartActual
Jan 1, 2015
Primary completionEst.
Sep 1, 2027was Sep 2025
CompletionEst.
Dec 1, 2027was Dec 2025
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • China-Japan Friendship Hospital · Beijing, China
Show 1 removed
  • China-Japan Friendship Hospital · Beijing, China
Nov 17, 2026
Primary completion
Sep 1, 2025→Sep 1, 2027
Nov 17, 2026
Study completion
Dec 1, 2025→Dec 1, 2027
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    1 site added, 1 site removed
    Show site
    • China-Japan Friendship Hospital · Beijing, China
    Show 1 removed
    • China-Japan Friendship Hospital · Beijing, China
    Primary completion Sep 1, 2025→Sep 1, 2027
    Study completion Dec 1, 2025→Dec 1, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06023134
Lead sponsor
Jingyi Ren
Responsible party
Jingyi Ren (Professor, China-Japan Friendship Hospital) — Sponsor-investigator
First posted
Sep 5, 2023
Start date
Jan 1, 2015
Primary completion
Sep 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Jingyi Ren
principal investigator · China-Japan Friendship Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion